Advertisement

Topics

Dyadic International posts higher revenue from R&D, new sublicensing collaborations

10:45 EDT 10 May 2019 | Proactive Investors

Dyadic International Inc (NASDAQ:DYAI) Chief Accounting Officer Ping Rawson says the Florida-based biotech reported a 119% increase in first-quarter research and development revenue compared to the same period a year ago.

Chief Scientific Officer Ronen Tchelet explained the value of its recently formed, exciting sub-licensing agreements with both Alphazyme and Serum Institute of India.

Original Article: Dyadic International posts higher revenue from R&D, new sublicensing collaborations

NEXT ARTICLE

More From BioPortfolio on "Dyadic International posts higher revenue from R&D, new sublicensing collaborations"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...